UC San Diego was awarded five COVID-19 Rapid Acceleration of Diagnostics (RADx) projects by the National Institutes of Health totaling nearly $33 million, which will fund efforts that range from managing a large data center to expanding testing in disadvantaged communities.
Armed with new fundamental insights into the interactions between lithium ions and electrolyte, UC San Diego engineers developed the first lithium metal battery that can be repeatedly recharged at temperatures as low as -60 degrees Celsius.
UC San Diego School of Medicine researchers are using stem cell-derived organoids to study how SARS-CoV-2 interacts with various organ systems. Their findings may help explain the wide variety in COVID-19 symptoms and aid the search for therapies.
Research from Herbert Wertheim School of Public Health and Human Longevity Science at UC San Diego suggests that light-intensity physical activity, including shopping or a casual walk, may protect against mobility disability in older women.
Scientists at University of California San Diego School of Medicine validated a more inclusive and comprehensive genetic tool, known as a polygenic hazard score (PHS), for predicting age of onset of aggressive prostate cancer.
Researchers at UC San Diego School of Medicine use bacteriotherapy to improve symptoms of atopic dermatitis.
UC San Diego researchers have launched a first-in-human Phase I clinical trial to assess the safety and efficacy of a gene therapy to deliver a key protein into the brains of persons with Alzheimer’s disease or Mild Cognitive Impairment, a condition that often precedes full-blown dementia.
Researchers at University of California San Diego School of Medicine identified new therapeutic targets for gastrointestinal stromal tumors (GISTs) that could lead to new treatment options for patients.
UC San Diego researchers report that individual immune response to SARS-CoV-2 may be limited by a set of variable genes that code for cell surface proteins essential for the adaptive immune system. The finding may help explain why COVID-19 immunity varies by individual.
The Psychedelics and Health Research Initiative at UC San Diego has received a $1.3 million grant from the Steven & Alexandra Cohen Foundation to fund a clinical trial investigating the therapeutic potential of psilocybin in treating phantom limb pain.